Concepedia

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot, François Guilhot, Françoise Huguet, Franck E. Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno Varet,

The Lancet Oncology · 2010 · 1.5K citations · 22 references

DOI

Concepts

References

22

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

, , +12

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

, , +10

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

, , +13

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Hagop Kantarjian, Charles L. Sawyers, Andreas Hochhaus et al. · New England Journal of Medicine · 2002 · 2K citations · Full text

, , +14

Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML

Catriona Jamieson, Laurie Ailles, Scott J. Dylla et al. · New England Journal of Medicine · 2004 · 1.5K citations · Full text

, , +17